Deregulation of the PI3 K/AKT/mTOR molecular pathway is associated with the progression of various cancers (Hussain et al. 2015; Ahmed et al. 2014; Du FY et al. 2019); thus, agents such as inhibitors/antagonists/agonists were structurally designed and formulated to target the above cascade in multiple cancers and CSCs, including BC. Here, MTOR is linked to breast cancer.